Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study

Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease

(2020) George Bakris et al.   HYPERTENSION

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine

(2020) Rajiv Agarwal et al.   EUROPEAN HEART JOURNAL

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

(2020) George L. Bakris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone in Healthy Volunteers

(2020) Tadakatsu Nakamura et al.   Clinical Pharmacology in Drug Development

Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study

(2019) Sadayoshi Ito et al.   JOURNAL OF HUMAN HYPERTENSION

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial

(2019) Rajiv Agarwal et al.   LANCET

A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases

(2019) Kitty J Jager et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients

(2018) Jean Jacques Noubiap et al.   HEART

Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association

(2018) Robert M. Carey et al.   HYPERTENSION

Effects of Intensive BP Control in CKD

(2017) Alfred K. Cheung et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Worldwide access to treatment for end-stage kidney disease: a systematic review

(2015) Thaminda Liyanage et al.   LANCET

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

(2015) Bryan Williams et al.   LANCET

Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease

(2014) Ivana Lazich et al.   SEMINARS IN NEPHROLOGY

KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Management of Blood Pressure in CKD

(2013) Sandra J. Taler et al.   AMERICAN JOURNAL OF KIDNEY DISEASES